Therma Bright Inc (TSX-V:THRM, OTC:TBRIF). announced that it has begun investigating opportunities to commercialize and monetize its artificial intelligence (AI)-driven Digital Cough Technology (DCT) as a remote therapeutic monitoring solution.
The company’s DCT platform can support faster and more accurate healthcare decision-making by improving the ability to collect, organize, and display cough and respiratory data to healthcare providers, according to Therma Bright.
It can also be used by public health workers such as epidemiologists to investigate patterns and causes of disease.
"The global penetration of smartphones, coupled with improved 4G/5G internet connectivity and AI-driven/machine learning data capture and analysis, has helped advance the healthcare IT space," Therma Bright CEO Rob Fia said in a statement.
"The COVID-19 pandemic was a wakeup call to our global communities, and the need to quickly and efficiently collect, capture and analyze critical healthcare data, such as digital cough technology, from a single patient to millions of people; allowing a clinic, healthcare practitioner, corporation and/or government entity to better determine the potential rise or prevalence of a chronic disease."
Additionally, the company announced that it has begun researching the Centers for Medicare and Medicaid Service (CMS) procedures for securing various Current Procedural Terminology (CPT) and Healthcare Common Procedure Coding System (HCPCS) billing codes for patient and practitioner reimbursements for its DCT as a remote patient monitoring solution.
It is working with its Venowave distribution network in Texas to expand sales of Venowave using nine temporary CPT and HCPCS reimbursement codes.
In tandem with its CMS effort, Therma Bright said it plans to complete its AI-driven DCT user-interface dashboard for its mobile, tablet and computer apps for healthcare practitioners.
This summer the company also plans to expand its global data collection efforts through a beta test being conducted throughout the US.
Therma Bright is a developer and partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies focused on providing customers and medical professionals with quality, innovative solutions that address some of today’s most important medical and healthcare challenges.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie